chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient became dizzy. Knees buckled. Pt. sat on floor and fell back but did not hit his head.
Face flushed, throat scratchy, had some SOB, no itching, blotched-light, swelling around eyes.
Patient complains of tingling and itchy of mouth and throat. Initial blood pressure was 148/80. 50mg of Benadryl given.
Well, it was first facial tingling on the left side (same side as shot)  but it gravitated in a more pronounced (and a little bit scary) way around the outer arch of my left eye socket. I started to massage it to just get it whatever it was moving and circulating. Then I figured it might be a good idea to get up and rotate my arm a little and jump around. This actually helped. The tingling and very slight numbness subsided after about three hours but today, a full 29 hours later, my left eye is twitchy. It's not a huge deal. I was in bed most of the day anyway but a nurse friend of mine said I should still responsibly report this.
Breakthrough case admission after 2 vaccines Pfizer 9/16/21 Lot# 301308A;  Pfizer 10/07/21 Lot# FE3590
chills; fever (Tmax 102.7F despite acetaminophen use); body/muscle aches; body/muscle aches; significant headache; fatigue; first dose on 16Dec2020 13:00/second dose on 05Jan2021 12:45; first dose on 16Dec2020 13:00/second dose on 05Jan2021 12:45; This is a spontaneous report from a contactable physician (patient). A 39-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK9231) via an unspecified route of administration at left arm on 05Jan2021 12:45 at single dose for COVID-19 immunization. Medical history included seasonal allergies. The patient's concomitant medications were not reported. The patient previously received the first dose of bnt162b2 (lot number: EH9899) via an unspecified route of administration at left arm on 16Dec2020 13:00 at single dose for COVID-19 immunization. Approximately 9 hours following the second dose (reported as 05Jan2021 22:30) patient started with chills and fever (Tmax 102.7F despite acetaminophen use), then significant body/muscle aches, significant headache, fatigue. Symptoms lasted 24hrs from that time. Fatigue lasted 36-48hrs. Patient received home use of acetominophen, Ibuprofen, Nurtec as treatment. No other vaccine in four weeks. No covid prior vaccination. No covid tested post vaccination. The outcome of the events was recovered in Jan2021.
4/27/2021 - Swollen lymph nodes, fatigue, body and head aches began on 4/27/2021 4/29/2021 - Covid-19 test (negative result) & Prescribed Prednisone 10mg 5-4-3-2-1 dosage on 4/29/2021 5/2/2021 - Revisited doctor due to continued fatigue, body and head aches.  Lymph nodes less swollen but still enlarged.  Blood test performed 5/3/2021 tested positive for re-activated Mononucleosis
no adverse effect; received dose of pneumovax23 that had been improperly stored; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's concurrent condition, medical history and concomitant therapy details were not reported.  On 14-AUG-2019, the patient was vaccinated with improperly stored pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) (strength and route of administration were not reported) lot # R033343, expiry date 03-AUG-2020 and lot # S012244 expiry, date 09-FEB-2021 for prophylaxis (Product storage error). The vaccines were exposed to a temperature of 0.0-degree Celsius in a time frame of 23 hours and 30 minutes. No previous temperature excursion was reported. The call was due to digital data logger. No adverse event was reported. No product quality complaint (PQC) was associated with this report.
Localized reaction observed 7/26/04 with 3x4cm well-demarcated nodule with central area of erythema on right thigh. No warmth or tenderness to palpation. No sign skin break down or neurosis. No systemic sxs: afebrile. Advised to monitor for adverse change.
Second dose was almost 1 year later; This case was reported by a consumer via interactive digital media and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose almost one year before the reporting date).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.  Additional details were provided as follows: The reporter was the patient. The age at vaccination was not reported. The patient had the Shingrix vaccination and the second dose was almost 1 year after the 1st dose, which led to drug dose administration interval too long.  The reporter was asking if the vaccine was still effective.
This spontaneous report was received from a pharmacist regarding a patient of unknown age and gender. Information on the concurrent condition, medical history and pertinent drug allergies of the patient were not reported. On 05-DEC-2015 at time- 08:00, the patient was vaccinated with improperly stored RECOMBIVAX HB lot # L025738 (expiry date, dose #, route, dose units and anatomical location were not specified). Concomitant medication was not reported. No adverse events were reported. The high temperature and low temperature at which the product was stored were 2.8 and 2.4 (units unspecified) respectively. There were no Product Quality Complaint (PQC) involved. This is one of several reports received from same reporter. Additional information has been requested.
PATIENT WAS ADMINISTERED VACCINE ONE DAY AFTER ITS BEYOND USE DATE OF 03/27/2022
Patient received 2nd dose of COVID vaccine today.  Pfizer vaccine was administered, but upon further review it was determined first dose was given on 3/2 as Moderna.  Patient tolerated both doses fine and was advised the second vaccine will still provide adequate protection so no additional doses are needed despite the mixed manufacturers.
having trouble breathing; he is coughing; can´t get to sleep; he's wheezing in his chest; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (having trouble breathing), COUGH (he is coughing), INITIAL INSOMNIA (can´t get to sleep) and WHEEZING (he's wheezing in his chest) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Jan-2021, the patient experienced DYSPNOEA (having trouble breathing), COUGH (he is coughing), INITIAL INSOMNIA (can´t get to sleep) and WHEEZING (he's wheezing in his chest). At the time of the report, DYSPNOEA (having trouble breathing), COUGH (he is coughing), INITIAL INSOMNIA (can´t get to sleep) and WHEEZING (he's wheezing in his chest) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment related information has been reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Three days after flu shot on 9/3, pain in neck and shoulder. Approximately 7-8 days after shot, weakness in left arm (site of shot) and left hand. Admitted at hospital on 9/15 for 3 days resulting in diagnosis of peripheral neuropathy - paresis left upper extremity. Physical therapy began 9/24 outpatient.
Patient began to complain of "tingling" to arms. On 11-1-13, employee states he began to have tingling and numbness to facial area. Employee referred to ER.
Large local reaction, 725 cm at subcut L arm.  Swelling, pain, erythema, fever.
Gave GARDASIL shot et pt reported feeling dizzy. Had pt lay down et got mom et doctor into the room. Heart rate 55-60/BP low/ pt responsive.
Pt was given injection in Left thigh with no complications.  She was speaking and walking.  Sitting in chair, Pt father said her name as nurse turned to look, observed pt slumped over to left side not responding, eyes rolled back in head.  Father stated "I saw her going and grabbed her."  Pt did not sustain head injury.  Nurse lowered pt to floor, she had lolli pop in her mouth jaw was clenched, body ridged, upper body shaking.  Her jaw relaxed, body still ridged, lolli pop was removed from mouth and pt was placed in rescue position on left side with nurse at head.  Blood pressure was obtained 50/36 pulse of 98  blood sugar was 77.  This activity lasted approx. 30-45 seconds.  Pt body began to loosen up, eyes opened, not responsive to commands.  After approx. 5 min pt began to recognize father.  911 was activated.  After approx. 12 min pt started to respond to name, and person.  She was able to answer simple questions.  blood pressure 70/50.  Pt was sat up on floor with nurse, given water and color began to return.  EMS arrived pt was transported via ambulance with father.
Information has been received from a focus group researcher concerning a 17 year old female who was vaccinated with GARDASIL. In April 2009, the patient experienced rash, swelling, nausea and dizziness. The reporter noted that therapy with GARDASIL was discontinued. The patient's rash, swelling, nausea and dizziness diminished within 3 days after stopping GARDASIL. The reporter considered the rash, swelling, nausea and dizziness to be other important medical event. Additional information has been requested.
I contracted COVID-19. I had a slightly elevated temperature above 98. I had a sore throat, dry cough, and general malaise. I received PAXLOVID from my doctor.
This initial spontaneous report was received on 11-SEP-2018 from a lawyer regarding a case in litigation and refers to a male patient of unknown age. Information regarding medical history, concurrent conditions and concomitant medications was not provided. On or about 20-MAY-2014, the patient was inoculated with ZOSTAVAX at Homecare and Hospice Care as recommended for routine adult health maintenance and for the long-term prevention of shingles. The vaccine did not prevent shingles, and the patient subsequently contracted a persistent strain of herpes zoster or shingles. On or about 09-SEP-2016, the patient was treated by Homecare and Hospice Care for the onset of a vesicular rash, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Patient started to feel warm and her face was red. She felt dizzy and like she needed to sit down right away. We checked her blood pressure and it was 105/84 with pulse 101. She was shopping the store and it was warm in the store and there were lots of people crowded in the aisles as it is right before Easter. We brought her back the pharmacy and had her sit on the bench. We gave her a bottle of cold water. She denied and swelling of the throat, tongue or face. She sat on the bench for about 10 minutes and the symptoms slowly resolved and she felt well enough to continue her shopping.
pt recv vax & 5wk later pt exp high levels of IgG & was dx w/GBS;
Muscle and joint pain/aches, mild headache, fatigue - lasted approximately 24 hours
12/12 DIZZINESS, BODY ACHES, CHILLS, NOSE STUFFY, GLANDS IN NECK SWOLLEN BILATERLY,  12/13 DECREASE IN BODY ACHES AND GLAND AND DIZZINESS, CHILLS REMAINED 12/14 CHILLS LESSENED, RASH AND ITCHING AND BURNING FROM INJECTION SITE HALF WAY TO ELBOW,  ONSET OF BRAIN FOG 12/15 ABOUT THE SAME AS YESTERDAY 12/12 TAKING ADVIL 200MG, EVERY 4 HOURS 12/15 TAKING NOTHING
13 days after my first dose of the Moderna Covid-19 vaccine, I developed an itchy rash around the site of injection.  The itch was mild, but I still have it 3 days later, and it seems to be larger but fading.
This spontaneous report was received from a physician via a company representative and refers to an unspecified number of patients of unknown age and gender (reported as "multiple"; "about 1 in every 8"). No information regarding the patients' pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On an unknown date, the patients were vaccinated subcutaneously with ZOSTAVAX injection 19400 PFU (dose, lot number and expiration date were not reported) for indication reported as herpes zoster. On unknown dates, the patients experienced an "indurated erythematous" around the injection site of the ZOSTAVAX. The size of the "indurated erythematous" was about 4 inches in diameter. The patients were treated for "indurated erythematous" with diphenhydramine hydrochloride (BENADRYL). On an unknown date (reported as "in about a week"), the patients recovered from "indurated erythematous" (reported as "it was resolved"). The patients sought medical attention (saw the physician). No product quality complaint was involved. The relatedness between "indurated erythematous" and ZOSTAVAX was not reported. Additional information has been requested.
severe pain in right buttocks and traveled down her right leg; mobility due to severe pain; This case was reported by a consumer via call center representative and described the occurrence of leg pain in a 71-year-old female patient who received Herpes zoster (Shingrix) (batch number 9X374, expiry date 10th October 2021) for prophylaxis.   The patient's past medical history included joint replacement. Concurrent medical conditions included spinal stenosis.   On 3rd July 2019, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 4th July 2019, 1 days after receiving Shingrix, the patient experienced leg pain (serious criteria clinically significant/intervention required) and mobility decreased (serious criteria clinically significant/intervention required). The patient was treated with tramadol and paracetamol (Tylenol). On an unknown date, the outcome of the leg pain and mobility decreased were not recovered/not resolved.   It was unknown if the reporter considered the leg pain and mobility decreased to be related to Shingrix.  Additional details were provided as follows: The patient developed severe pain that started in her right buttocks and traveled down her right leg.  The patient stated this pain was similar to spinal stenosis pain, but described it as severely worse than usual. The patient sought medical treatment with her MD, received medication (Tramadol and Tylenol) to treat pain and physical therapy, and was using a walker to assist with mobility due to severe pain.  The patient did not consent to healthcare professional follow up.  The patient did not consent to follow up.
Tendinitis, tenosynovitis or inflammation of tendon sheath lining biceps muscle. BICIPITAL.
Recd inject 3pm; onset vertigo 8pm, progressively severe over next 30 hrs, nausea, fever 101, localized swelling & tenderness @ inject site. Sxs subsided spontaneously in 36 hrs.
Migraine, Sore Throat, Bad cough, coughing blood, weak & tired, 5 days + so far...
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On or about 11-OCT-2016, the patient was inoculated at a pharmacy with the ZOSTAVAX (lot number, dosage and route of administration not provided), as recommended for routine adult health maintenance and for the prevention of shingles. ZOSTAVAX did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster. On or about 13-APR-2017, the patient was treated by a physician for the onset of a severe vesicular rash, which was diagnosed as herpes zoster, or shingles. As a direct and proximate result of the ZOSTAVAX, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events is unknown. Additional information has been requested.
Day after had sweats and arm pain, then was fine. Tuesday night felt heart a little but didn?t think anything serious of it. Then Wednesday-Friday had immense heart pain. Was only getting 4 hours of sleep because it was hard to sleep as heart would not stop palpitating heavily all throughout the day and had to apply pressure to get that little amount of sleep  on that side. Heavy fatigue. Wheezing. Would feel pain even more when laid down. Chest felt tight and pain on shoulder blade behind heart one day, left side of neck, and then ear infection on left ear by Friday (aug 27th) which I started antibiotics for just recently (sept 1st) as it lingered. Heart pain lingered as well but by that Saturday (aug 28th) slowly got better to stop the nonstop palpitations and sleep properly. A week later heart pain was a lot better, but hurting still slightly at moments. Especially when about to sleep. Now two weeks later I?m okay with heart, ear pain still there at moments though and cautious.
Patient came in today for their appointment for their second dose of Moderna. Patient was screened and immunized by one of our nurses. According to the patient's CDC card, they received their first dose of Moderna on 1/13 and therefore they got their second dose 1 week too early. Per CDC, a second dose given earlier than the minimum interval allowed (i.e., sooner than the 4-day grace period) is considered invalid and should be repeated no sooner than either 21 days (Pfizer-BioNTech COVID-19 Vaccine formulation) or 28 days (Moderna COVID-19 Vaccine) following the invalid second dose in order to complete the primary series. Patient was counseled and an appointment was made for March 3rd. Patient felt fine after their waiting period.
Chills; Body aches; Fever over 102.5; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0158) via an unspecified route of administration in the left arm on 21Apr2021 at 13:00 (at the age of 37-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included pseudoephedrine sulfate, loratadine (ALLERCLEAR D) 24hr and loratadine, pseudoephedrine sulfate (CLARITIN-D); both on unknown dates for unspecified indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: Er8732) via an unspecified route of administration in the left arm on 01Apr2021 at 12:15 (at the age of 37-years-old), as a single dose for COVID-19 immunisation. The patient previously received pertussis vaccine (MANUFACTURER UNKNOWN) on unknown date for an unspecified indication and experienced allergy to vaccine. On 22Apr2021 at 15:00, the patient experienced chills, body aches and fever over 102.5. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On 22Apr2021 at 15:00, the patient underwent lab test and procedure which included body temperature and result was shown as 102.5 (units unspecified). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, body aches and fever over 102.5 were resolving at the time of this report.    No follow-up attempts are needed. No further information is expected.
I am pretty sure I had my first dose on Friday, 04/16/2021 at 04:00 and I do have email confirmation of this but my card indicates 04/17/2021. Within 24 hours I had significant fatigue, mild fever, soreness, and brain fog. I was due for a period and it was three weeks late. I did take a pregnancy test and it was Negative. I had heard at that point that other women were reporting having delayed period. It did eventually come but I can't recall how it was but it did not happened.
The patient received the one vaccine in his arm on the 13th. By that evening, the arm started to swell and was very painful. He opted out of football practice and stayed home. The pain was severe and the right arm became numb. He was nauseous all evening and had multiple bouts of dry heaves but never fully vomited. By morning, the numbness resolved, but he still felt mildly nauseous. He was seen at 09:45 on the 14th. The nausea resolved and he did not have any stomach tenderness. The site of Injection was raised, slightly pink and tender. He said he felt better but did not want anyone to touch the arm at the site of injection.
Patient was given a primary Pfizer vaccine that expired 11/30/2022. Pt was fine no adverse reactions occured while she was in office for 20-minute observation.
There were vaccines drawn from an expired Moderna vial. The vial expired 12/09/21 and the dose was given 12/10.  Patient has not exhibited adverse events post vaccination.  Moderna was called to inquire about further steps and whether or not the patient needs to be contacted to be revaccinated. The case was escalated and the turn around time for a response is 3 days.
Nerve pain in whole arm of injection (left), aching wrist in right arm (nerve pain in wrist)- nerve pain off and on, better if not moving left arm at all lasted though 7/17/11. Morning of 7/18/11 swelling of top upper arm/tight muscle and viable (mildly) to eye (looks like whole deltoid is well defined) @ injection site.
Mother phoned on 9/5/06, stating that child had redness, swelling & blisters on left leg, two days after injuection. No change in behavior or pain and parent indicated that blisters were gone. Advised that this was localized reaction. Mother then brought child to the Health Dept. on 9/8/06. Visualized peeling, scabbed area and redness in a circle to left upper leg, by RN. No fever, temp 97.0 Degrees F. Advised to call pediatrician if not greatly improved by Monday, 9/11/06. Also advised that if child developed fever or other s/s to see pediatrician immediately.
I started throwing up that evening. For three months I would get a strange feeling like a bubble in my throat, then I would throw up. Now I have issues when I drink I start coughing.
Day of Injection: Mild pain to left deltoid. Day one post injection: Left arm pain (difficulty in raising arm pain 8/10 if moved), extreme chills and body aches, itchiness and redness around injection site approx. 3 inches by 2 inches, progressing during day to red raised patches with itchiness. Day two post injection: raised patches more defined with raised border surrounding rash site.